The field of oncology has been revolutionized by the advent of targeted therapies, shifting the paradigm from traditionally cytotoxic, non-specific treatments to a more personalized, precision-based approach. This article delves into the recent advancements and potential of targeted therapy in oncology.
Unlike conventional chemotherapy, targeted therapy works by interfering with specific proteins that help tumors grow and spread, thereby minimizing damage to healthy cells. It focuses on the molecular and cellular changes specific to cancer, which includes overactive signaling pathways, mutations driving cancer growth, and tumor angiogenesis.
Recent years have seen a surge in the development and approval of targeted therapies. Tyrosine kinase inhibitors (TKIs), such as imatinib and erlotinib, have shown success in treating chronic myeloid leukemia and non-small cell lung cancer, respectively. Monoclonal antibodies like trastuzumab have been effective against HER2-positive breast cancer. Additionally, breakthroughs in immunotherapy, including immune checkpoint inhibitors and CAR-T cell therapy, have opened new avenues in treating various malignancies.
The potential of targeted therapy is vast, with ongoing research exploring novel targets and combination therapies. However, challenges persist. Resistance to therapy, both primary and acquired, poses a significant hurdle. Heterogeneity within tumors also complicates treatment, as different cells may respond variably to the same therapy. Furthermore, the high cost of these therapies can limit accessibility.
In conclusion, targeted therapy heralds a new era in cancer treatment, offering the promise of increased specificity and reduced toxicity compared to traditional chemotherapy. While challenges persist, continued research and innovation hold the key to unlocking its full potential, paving the way for a more personalized and effective approach to cancer treatment.
1.
Global warming could be driving up women's cancer risk, find researchers
2.
Blood tests can predict the risk of relapse after a bone marrow transplant in patients with acute myeloid leukemia.
3.
Survey shows cancer anxiety has impact well beyond the individual diagnosed
4.
MRI can save rectal cancer patients from surgery, study suggests
5.
Glioma Outcomes Shaped by Subtype More Than Tx Sequence
1.
Rehabilitation After Organ-Conserving Cancer Surgery
2.
Practical Breakthroughs in Oncology Across Clinical Settings
3.
Gynecologic Oncology: Advances, Education, and Clinical Excellence
4.
Breaking Down the Different Types of Lymphoma: What You Need to Know
5.
RNA-Targeting Chimeras in Cancer: Mechanisms, Clinical Advances, and Future Directions
1.
International Conference on Innovations in Critical Care for Oncology and Cardiology
2.
International Conference on Oncology, Cardiology and Critical Care Policy
3.
International Conference on Oncology, Cancer Prevention and Public Health
4.
International Conference on Cancer Nursing and Rehabilitation Strategies
5.
International Conference on Best Practices in Oncology, Cardiology and Critical Care
1.
Breaking Ground: ALK-Positive Lung Cancer Front-Line Management - Part II
2.
First Line Combination Therapy- The Overall Survival Data in NSCLC Patients
3.
Cancer Care: From Awareness to Recovery
4.
Revolutionizing Treatment of ALK Rearranged NSCLC with Lorlatinib - Part VII
5.
A Conclusive Discussion on CROWN Trial and the Dawn of a New Era in Frontline Management of ALK+ NSCLC
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation